Mathematical and Computational Modeling Prototype to Understand the Evolution of Parkinson’s disease using Four Differential Equations
Objective: Apply four differential equations to generate projections considering the effect of dopamine on Parkinson’s disease progression, leading to the development of an initial prototype…Methodological considerations supporting a time-to-event primary endpoint in the PADOVA study in early-stage Parkinson’s disease participants on stable symptomatic treatment
Objective: To provide the methodological rationale for using a time-to-event (TTE) primary endpoint in the PADOVA study. Background: The use of symptomatic medications represents a…CAP-003, a CNS-targeted IV-delivered AAV Gene Therapy Developed for Patients with Parkinson’s Disease associated with GBA1 Mutations
Objective: CAP-003 is a next-generation gene therapy candidate, comprising a novel brain-tropic capsid paired with hGBA1 cargo, that was developed for administration as a single…Quality of Life Improvements in Parkinson’s Disease for Those Treated with Photobiomodulation Plus Exercise: A Sham-Controlled Study
Objective: To assess whether exercise alone, or exercise combined with photobiomodulation (PBM) can improve the health-related quality of life (QoL) for people with Parkinson’s disease…A Phase 2 Study of Risvodetinib in Untreated Parkinson’s Disease
Objective: Risvodetinib was evaluated in a randomized, double-blind, placebo controlled Phase 2 trial at three doses to determine the safety and tolerability in patients with…Effect of Allogeneic Bone-Marrow Derived Mesenchymal Stem Cell Therapy on Quality of Life in Patients with Parkinson’s Disease
Objective: To assess the impact of intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) infusions on the quality of life (QoL) of patients with…A Systematic Site Selection Approach to Ensure Efficient and Diverse Participant Recruitment to a Large-Scale Multi-Arm, Multi-Stage Platform Trial for Parkinson’s
Objective: To select up to 40 delivery sites to successfully recruit and retain a participant population representative of people with Parkinson’s disease (PwP) in the…EJS ACT-PD: An Ongoing Initiative to Support Innovation and Sustainability of a Multi-Arm, Multi-Stage Platform Trial for Parkinson’s Disease
Objective: To provide continued consortium expertise to provide ongoing innovation and long-term sustainability in a multi-arm, multi-stage (MAMS) disease modification trial for Parkinson’s disease (PD).…Lithium Therapy Associated with Reductions in Serum Neurofilament Light Chain (NfL) in Parkinson’s Disease.
Objective: To assess the effects of lithium aspartate and lithium carbonate therapy for 24 weeks on serum NfL in Parkinson’s disease (PD). Background: Lithium has…First-In-Human Single and Multiple Ascending Dose Trial Design of LY3962681, a Novel Intrathecally Delivered siRNA Targeting α-synuclein mRNA for the Treatment of Patients with Parkinson’s Disease
Objective: Development of a Phase 1 clinical trial evaluating LY3962681, a novel, intrathecally delivered siRNA directly targeting α-synucleinmRNA (SNCA) to reduce α-synuclein protein (ASYN), for the treatment of…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 19
- Next Page »